Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT00656019
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
- Undergoing core needle biopsy for a breast abnormality suspicious for breast cancer.
- Has undergone a core needle biopsy demonstrating breast cancer and has not yet had any
further therapy, provided the core needle biopsy is available for analysis.
- No prior therapy for breast cancer within the past 5 years.
- 18 years of age or older.
- Ability to understand and the willingness to sign a written informed consent document.
- History of parathyroid disease, hypercalcemia, or kidney stones.
- Supplemental vitamin D other than from a standard multiple vitamin or from standard
formulations of calcium and vitamin D (eg, calcium citrate with vitamin D) within the
prior 6 months.
- History of renal failure requiring dialysis or kidney transplantation.
- Pregnant or nursing
- Receiving supplemental calcium > 1200 mg calcium per day during study.
- Initial treatment of breast cancer will not be with breast-conserving surgery or
- Locally-advanced breast cancer
- Plans for neoadjuvant chemotherapy, hormonal therapy, or other systemic therapy
- Plans for preoperative radiation therapy
- Plans for breast cancer surgery, and does not allow for at least 10 days of vitamin D
- Any condition potentially interfering with subjects ability to comply with taking
- Any medical condition that would potentially interfere with vitamin D absorption, such
as celiac sprue, ulcerative colitis.
- Current participation in another research study that would increase risk to subject,
in the opinion of the investigators
drug: Vitamin D
School of Medicine
300 Pasteur Drive
Stanford, CA 94305